Drug
Chf6001 Dry
Chf6001 Dry: highest development phase Phase 1, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF6001 dry powder inhaler (DPI) NCT06892756 | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) |
Latest
No recent events.
Follow Chf6001 Dry on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.